Correction: Continuous Subcutaneous Foslevodopa/Foscarbidopa in Parkinson ’s Disease: Safety and Efficacy Results From a 12-Month, Single-Arm, Open-Label, Phase 3 Study

Source: Neurology and Therapy - Category: Neurology Source Type: research